New treatment for immune thrombocytopenia
This product Tavlesse popped up in an advert on BMJ website. I find it curious that the drug appeared last year (article dated 09-07-2020) -just ahead of the vaccine rollout. I think I saw thrombocytopenia being one of the adverse effects of the jab. Handy then, to have this new treatment ready for “emerging diseases.”
special instructions to access this link – copy the link and send it to google search, then get the cached version.
Spanish company Grifols (MCE: GRF) has begun European delivery of Tavlesse (fostamatinib) to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments.
Tavlesse, which was approved by the European Commission earlier this year, is already available in Germany and the UK, with a phased rollout across the rest of Europe planned over the next 18 months before expanding into Turkey.
Grifols has exclusive rights to the drug in chronic ITP, as well as any potential future indications like autoimmune hemolytic anemia, and IgA nephropathy, in Europe and Turkey, thanks to a collaboration and license agreement reached with USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) in January 2019.
The same drug is also commercially available in the USA under the brand name Tavalisse, the first and only spleen tyrosine kinase inhibitor indicated in adult patients with chronic ITP who have had an insufficient response to a previous treatment.
This is the first non-plasma product that the Barcelona-based company’s flagship Bioscience Division has launched in Europe, though Grifols has said that it expects to further strengthen and complement its industry-leading portfolio through additional innovative in-licensing agreements to treat existing and emerging diseases.